Genelux (GNLX) Q1 2025 earnings summary

Executive summary

• Focused on developing oncolytic viral immunotherapies for aggressive solid tumors, with Olvi-Vec as the lead candidate in late-stage clinical trials and advanced in multiple cancer indications.

• No products approved for sale; operations centered on R&D, clinical trials, and building commercialization capabilities.

• Net loss of $7.5 million for Q1 2025, with an accumulated deficit of $258.9 million as of March 31, 2025.

• Completed public offerings in March 2025, raising $9.6 million and $10.5 million, extending cash runway to Q3 2026.

• Strengthened leadership with appointment of new CFO, Matthew Pulisic, effective January 30, 2025.

Financial highlights

• Q1 2025 revenue was $0, compared to $8,000 in Q1 2024 from a license agreement.

• Research and development expenses increased to $4.7 million from $4.0 million year-over-year, mainly due to higher clinical trial costs.

• General and administrative expenses decreased to $3.1 million from $4.1 million, primarily due to lower stock compensation.

• Net loss for Q1 2025 was $7.5 million, or $0.21 per share, compared to $7.9 million, or $0.29 per share, in Q1 2024.

• Cash, cash equivalents, and short-term investments totaled $35.1 million as of March 31, 2025.

Outlook and guidance

• Cash runway expected to last until Q3 2026, but additional funding will be needed for full development and commercialization.

• Ongoing Phase 3 trial for Olvi-Vec in ovarian cancer and Phase 2 trial in NSCLC; topline results for Phase 3 expected in H1 2026, interim lung cancer data in 2H 2025.

• Anticipates increased R&D and commercialization expenses as clinical programs advance.